secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0001104659-22-047835
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA board member Lengauer to depart; appoints Timothy Reilly as director
----------------------------------------------------------------------------

- Christoph Lengauer will not stand for re-election at June 30, 2022 annual meeting; departure not due to disagreement.
- Timothy Reilly, Ph.D. appointed to board effective immediately; will serve as Class II director until 2024.
- Reilly previously SVP at Bristol Myers Squibb, currently Chief Development Officer at HotSpot Therapeutics.
- As non-employee director, Reilly receives initial option for 19,200 shares plus annual $40,000 cash retainer.
- Reilly will join Nominating and Corporate Governance Committee on June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/tm2213066d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-047835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer